Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases

Silvia González-Martínez,1,2, David Pizarro,3, Belén Pérez-Mies,3,4,5,6, Tamara Caniego-Casas,3, José Luis Rodríguez-Peralto,5,7,8, Giuseppe Curigliano,9,10, Alfonso Cortés,11, María Gión,11, Javier Cortés,5,12,13,14,15,* and José Palacios,3,4,5,6,*

Abstract: Background: The characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished. Methods: To investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of BC and their CM, the most frequent were amplification of MYC and MDM4, and mutations in TP53 and PIK3CA. Survival was related to histological grade, tumor surrogate molecular type and TP53 mutations in the univariate analysis but only the tumor surrogate
molecular type remained as a prognostic factor in the multivariate analysis. Conclusions: The TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.

**Keywords:** breast cancer; metastasis; skin; NGS; mutations; pathology; immunohistochemistry

### 1. Introduction

Breast cancer (BC) is the most prevalent malignancy in females and is the leading cause of cancer death in women [1]. We can distinguish between different groups of BC according to the molecular profile as those that express Estrogen Receptor (ER) and/or Progesterone Receptor (PR) (75%), those that express Epidermal Growth Factor Receptor 2 (Her2) (15%) [2], and tumors that do not express any of these three markers, the triple-negative (TN) tumors (10–20%) [3]. According to these characteristics, we can apply a surrogate molecular classification that distinguishes four surrogate molecular types of BC: luminal A-like, luminal B-like (HER2− and HER2+), HER2+ (non-luminal), and triple negative (TN) [4].

Metastasis accounts for the majority of deaths from BC [5]. It is a complex process in which the cells of a primary tumor are propagated to distal organs, showing uncontrolled growth in these tissues [6,7]. Normally, BC metastasize to the lung, bone, and brain [8]. Moreover, BC is the tumor most prone to develop skin metastases in females [9].

Skin metastases are the result of lymphatic embolization, hematogenous or contiguous spread [10] and are present in around 24% of patients with metastatic BC [9,11–16]. In addition, due to the high incidence of BC, these skin manifestations are the most common metastases among women seen by dermatologists, specifically, 69% of these metastases come from BC [13].

Cutaneous breast metastases tend to develop in the vicinity of the primary tumor in the skin of the breast and chest wall, although they can also develop in the abdomen, extremities, head, or neck [9,12,13]. In addition to being able to develop in different locations, breast cutaneous metastases (CM) can manifest in a wide variety of ways. Nodules are the most common presentation (80%), but there are other patterns [11,13] such as telangiectatic pattern with an incidence of 8–11%, erectile pattern with an incidence of 3–6.3%, carcinoma en cuirasse with an incidence of 3–4% and neoplastic alopecia with an incidence of 2–12% [11,13].

All BC metastases, regardless of subtype, usually occur late in the disease, in the later stages of the disease course. Brownstein et al. [17] observed that skin metastasis was the presenting sign of the disease in only 3% of cases of metastatic BC. Kong et al. [15] observed that 56.8% of the patients had more than one visceral metastasis at the time of diagnosis of CM. Therefore, when diagnosed, the primary tumor is widespread and may not be treatable (palliative care, surgical excision, or complete mastectomy is provided) [18]. All this confers a poor prognosis, with an average survival of 3 to 6 months, with few differences regarding whether the lesions are single or multiple, with mortality exceeding 70% in the first year after diagnosis [19].

Since there are few series evaluating the molecular alterations of CM and most do not include the analysis of both the primary tumor and CM, the objective of this study was to compare the molecular alterations of matched primary BC and their CM in a series of 33 patients to better understand the genes implicated in BC progression and to identify potential therapeutic targets.
2. Materials and Methods

Compliance with Ethical Standards: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The use of patient samples to meet the objectives of this study was approved on 14 May 2021 by the Ethics Committee of the Hospital Ramón y Cajal (ethical approval code: 30-21).

2.1. Histology

Histological sections of all primary tumors and their metastases were reviewed by two experienced pathologists (J.P and B.P.-M.). Histological typing and grading was performed according to WHO recommendations [4]. Lymphovascular invasion (LIV) was also evaluated in primary tumors. Cutaneous lesions were diagnosed as metastases from BC based on a biopsy, excluding cases with direct extension from a subjacent breast lesion.

2.2. Immunohistochemistry

All 33 primary tumors and 33 metastases underwent an immunohistochemical study for the expression of estrogen receptors (ER), progesterone receptors (PR), HER2 and Ki67. Immunostaining was performed using the EnVision detection system (K5007, Agilent Dako, Glostrup, Denmark) using the following antibodies: ER (clone EP1, Agilent Dako Omnis, Glostrup, Denmark), PR (clone PR 1294, Agilent Dako Omnis, Glostrup, Denmark), HER2 (SK001, clone poly, Agilent Dako autostainer, Glostrup, Denmark), and Ki-67 (clone MIB-1, Agilent Dako Omnis, Glostrup, Denmark). Evaluation of ER, PR, and HER2 expression was performed according to American Society of Clinical Oncology and the College of American Pathologists (ASCO-CAP) guidelines [20]. HER2 equivocal cases (2+) underwent FISH analysis, using the PathVysion HER-2 DNA Probe Kit (PathVysion II kit, Abbot Laboratories, Abbot Park, IL) on complete tumor sections. Results were interpreted according to 2018 ASCO-CAP guidelines [20].

In the 7 invasive lobular carcinomas, the expression of E-cadherin (clone NHC-38, Agilent Dako Omnis, Glostrup, Denmark) was studied to confirm the histological type. Androgen receptor (AR) (SP107 Cell Marque, Ventana Medical Systems, Rocklin, CA, USA) was also determined to evaluate the possible apocrine phenotype in 12 primary TN tumors and their metastases.

Tumors were classified into different surrogate molecular types as Luminal HER2-, Luminal HER2+, HER2 (non-luminal), and TN.

2.3. Massive Parallel Sequencing

Sufficient DNA for sequencing was obtained from the 33 primary breast carcinomas and their corresponding CMs. Areas with >30% of tumor cells were obtained by “punching” paraffin blocks in selected areas previously marked on hematoxylin/eosin (H&E) slides. The QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA) was used to extract DNA from all samples. Quality of DNA samples was measured using TapeStation (Agilent 2200 TapeStation, Santa Clara, CA, USA), whereas quantification was performed by QUBIT 2.0 (Thermo Fisher Scientific Qubit 2.0 Fluorometer, Waltham, MA, USA).

A custom gene panel was designed using the SureDesign platform by Agilent Tech. (Santa Clara, CA, USA) to consistently target 61 genes (AKT1, ARID1A, ARID1B, ARID5B, ATR, BCO1, BRCA1, BRCA2, BRF, CASP8, CCNE1, CDH1, CDH4, CDH19, COL1A1, CSMD3, CTCF, CTNNB1, EGFR, ERBB2, ESRI, FBXW7, FGFR1, FGFR2, FOXA2, GRB7, GSDMB, MAP2K4, KRAS, MAP3K1, MLL3, MLH1, MKI67, MSH2, MSH6, MYC, NCOR1, NF1, NRAS, PGAP3, PIK3CA, PIK3R1, PMS2, PNMT, POLE, PPP2R1A, PRPF18, PTEN, KMT2B, RB1, RPL22, SPOP, STARD3, TAF1, TBX3, TCAP, TP53, VGLL1, ZNF217, ZNF703). For library construction, a modified protocol for Agilent SureSelectXT FFPE was selected based on Covaris AFA fragmentation of DNA (Covaris, Woburn, MA, USA) and
subsequent probe-mediated hybridization capture. Sequencing of equimolar libraries was performed using the Ion S5™ Torrent (Thermo Fisher Scientific, MA, USA).

Bioinformatics analysis was carried out using a specific pipeline using Novoalign V3 (2021) (http://www.novocraft.com/products/novoalign/ accessed on 4 February 2022) as aligner and VarScan [21] as variant-caller, with no filters. Variant annotation was performed using the VEP from Ensembl version 88 (http://www.ensembl.org/info/docs/tools/vep/index.html accessed on 4 February 2022), which corresponds to the hg38 version of the human reference genome. Variants were latterly filtered using the functional information (taking only deleterious variants), the variant allele frequency (>0.05), and the strand-bias from both the variant and the reference allele. If normal tissue was available, those variants also present in the normal component were excluded. Finally, visual inspection was performed as the final selection criterion using the IGV browser [22].

In addition, 11 mutations were confirmed by Sanger sequencing, 3 in the \textit{PIK3CA} gene (Pt3, Pt14 and pt36), 6 in the \textit{TP53} gene (Pt1, Pt2, Pt4, Pt10 and Pt11), and 2 in the \textit{ERBB2} gene in the samples (pt13). (Supplementary Table S1).

2.4. Fluorescent In-Situ Hybridization on Tissue Microarrays

Since our panel was not designed to detect CNVs, a tissue microarray (TMA) was constructed to evaluate gene copy number variations in \textit{CCND1}, \textit{MYC}, \textit{FGFR1} and \textit{MDM4}, the genes most frequently amplified in BC, by Fluorescent In-Situ Hybridization (FISH). Only 20 matched primary tumors and metastases (40 samples) were included in the TMA due to sample limitation after the initial immunohistochemical/molecular study. Chromosomal alterations were evaluated by FISH on TMA sections using the following probes: \textit{SPEC CCND1/CEN11, MYC/CEN8, FGFR1/CEN8, and MDM4/1p12 dual color Probe Kit} (Zytovision GmbH, Bremen, DE). FISH slides were observed with a fluorescence microscope at 100X with immersion oil. A detailed scoring of at least 20 neoplastic cells per sample was performed. Amplification was considered when the tumor cell population had at least twice as many gene signals than centromere signals of the respective chromosome (ratio \(\geq 2\)), and polysomy when the average of centromere signals on tumor cells were >3.

2.5. Statistical Methods

The Kaplan–Meier method was used to calculate overall survival according to clinicopathological characteristics (age, pT, pN, histological type, surrogated molecular type, LIV, histological grade, clinical stage, metastasis location, and neoadjuvant therapy) and mutations in \textit{TP53} and \textit{PIK3CA} genes. Cox proportional hazards models were used to investigate the association between mortality and clinicopathological and molecular features.

3. Results
3.1. Case Selection

A total of 33 patients diagnosed with BC and CM between 2005 and 2020 from the Pathology Department in Ramón y Cajal University Hospital (Madrid, Spain) and in 12 de Octubre University Hospital (Madrid, Spain) were selected, all had available paired samples (primary tumor and CM).

3.2. Clinicopathological Features

Clinicopathological features of all 33 primary samples are presented in supplementary Table S2 and summarized in Table 1. The median age of the patients at diagnosis was 63.5 years old (range 29 to 84), 57.6% of patients were older than 60 years.
Table 1. Clinicopathological features of the 33 patients.

| Clinicopathological Features | Categories       | n (%)   |
|------------------------------|------------------|---------|
| **Sex**                      | Female           | 33 (100)|
| Age                          | <60              | 14 (42.4)|
|                              | >60              | 19 (57.6)|
| Cutaneous metastases location| Local *          | 15 (46.9)|
|                              | Distance         | 17 (53.1)|
|                              | NA               | 1       |
| Menopausal status at diagnosis| Yes             | 27 (90) |
|                              | No               | 3 (10)  |
|                              | NA               | 3       |
| **pT**                       | 1                | 5 (18.5)|
|                              | 2                | 14 (51.9)|
|                              | 3                | 5 (18.5)|
|                              | 4                | 3 (11.1)|
|                              | NA               | 6 **    |
| **pN**                       | 0                | 8 (30.8)|
|                              | 1                | 10 (38.5)|
|                              | 2                | 2 (7.7) |
|                              | 3                | 6 (23)  |
|                              | NA               | 7 **    |
| Clinical stage               | I                | 4 (12.5)|
|                              | II               | 5 (15.6)|
|                              | III              | 14 (43.7)|
|                              | IV               | 9 (28.1)|
|                              | NA               | 1       |
| **Histological Grade**       | 1                | 1 (3)   |
|                              | 2                | 13 (39.4)|
|                              | 3                | 19 (57.6)|
| **LIV**                      | Yes              | 11 (33.3)|
|                              | No               | 22 (66.7)|
| Immunohistochemical markers  | ER+              | 19 (57.6)|
|                              | PR+              | 11 (33.3)|
|                              | HER2+            | 5 (15.2)|
|                              | ≤15%             | 9 (27.3)|
|                              | 16–29%           | 5 (15.2)|
|                              | ≥30%             | 19 (57.6)|
| Surrogated molecular type    | TN               | 12 (36.4)|
|                              | Luminal HER2-    | 16 (48.5)|
|                              | Luminal HER2+    | 3 (9)   |
|                              | HER2+ (non-luminal)| 2 (6)   |

* Local lesions refer to lesions that presented on the skin of the breast/thorax. ** Patients diagnosed at stage IV did not undergo surgery and did not have pT and pN data.

According to the immunohistochemical profile, 16 cases (48.5%) were Luminal HER2-surrogate molecular type, 3 cases (9%) were Luminal HER2+, 2 cases (6%) were HER2+ (non-Luminal), and 12 cases (36.4%) were TN.

Examining the distribution of histological types, 24 cases (72.7%) corresponded to invasive breast carcinomas of non-special type (BCNST), the rest were special histological types. The largest group of 7 cases (21.2%) corresponded to invasive lobular carcinoma (ILC), one case (3%) was a matrix-producing (chondroid) metaplastic carcinoma, and one case was an apocrine carcinoma (3%).
3.3. Immunohistochemistry and HER2 FISH

3.3.1. Surrogate Molecular Types

The surrogate molecular type of the tumors and metastases was confirmed by IHC and FISH. The most frequent type of primary tumor was Luminal HER2- followed by TN. The molecular type changed between the primary tumor and its CM in 5 patients (15%), the most common being from luminal to TN (Table 2).

Table 2. Surrogate molecular type change between primary tumors and their cutaneous metastasis.

| Tumor       | Surrogated Molecular Type |
|-------------|---------------------------|
| Pt7_Primary | Luminal HER2-             |
| Pt7_Metastasis | TN                       |
| Pt18_Primary | Luminal HER2-             |
| Pt18_Metastasis | TN                       |
| Pt29_Primary | Luminal HER2-             |
| Pt29_Metastasis | TN                       |
| Pt14_Primary | Luminal HER2+             |
| Pt14_Metastasis | Luminal HER2-           |
| Pt32_Primary | Luminal HER2-             |
| Pt32_Metastasis | Luminal HER2+           |

In case Pt14, HER2 amplification was lost in the metastasis; on the other hand, in case Pt32, HER2 was overexpressed in the metastasis due to polysomy of chromosome 17.

3.3.2. Androgen Receptor in Triple-Negative Cases

AR expression was studied in 12 TN primary tumors and their metastases by IHC, since AR expression in TNBC is related with the apocrine molecular type [23]. In this series, 3 out 12 TNBC expressed AR and expression was concordant in primary tumors and the associated metastases.

3.4. Molecular Characterization

3.4.1. Most Frequently Altered Genes in Primary Tumors and Cutaneous Metastases

The following molecular analysis is based on 66 samples (33 primary tumor and 33 CM) for mutation analysis and 40 samples (20 primary tumor and 20 CM) for CNV analysis. Figure 1 shows the mutations and CNVs found in 29 pairs. In 4 cases, no mutations or CNVs were found, and all were Luminal HER2- cases. Molecular alterations were detected in 12 TN, 12 Luminal HER2-, 3 Luminal HER2+ and 2 HER2+ (non-Luminal) primary tumors. The number of mutations ranged between 1–5. A summary table with the type of mutation and CNVs found in each of the samples is presented in supplementary Table S3.

Among the 33 matched cases, TP53 was mutated in 13 primary tumors (39.4%) and in 14 CMs (42.4%). PIK3CA was mutated in 13 primary tumors (39.4%) and 15 CMs (45.4%). NF1 was mutated in 3 of the primary tumors (9%) and 4 CMs (12.1%). AKT1 was mutated in 3 primary tumors (9%) and 3 CMs (9%). ERBB2 was amplified or there was polysomy in 5 primary tumors (15.15%) and 5 CM (15.15%). Among 20 matched cases, MYC was amplified in 3 primary tumors (15%) and 5 CM (25%). MDM4 was amplified in only 3 CM (15%). FGFR1 CNVs (amplification or polysomy) were observed in 2 primary tumors (10%) and 2 CMs (10%). Finally, CCND1 was amplified in 1 primary tumor (5%) and 1 CM (5%). Table 3 shows a summary of these alterations distributed by surrogate molecular types.

Analyzing TP53 and PIK3CA mutation frequencies in the CMs of BC cases diagnosed at early stages (I-II) versus those diagnosed at advanced stages (III-IV), we observed that they were very similar. The mutation frequency for both genes of cases diagnosed at early stages was 44.4%. In cases diagnosed at advanced stages the frequencies were 47.8% for TP53 and 52.2% for PIK3CA. Thus, there were no statistically significant differences between the two groups.
Enriched Molecular Alterations in Cutaneous Metastases

Additional molecular alterations were observed in the CM, either mutations or CNVs, in 16 patients (48.5%) (Figure 2). In 7 cases (21.2%) there was more than one additional alteration in the CM. Table 4 shows the distribution of these alterations by surrogate molecular types.

Figure 1. Distribution of mutations and CNVs in this series. The figure shows paired samples corresponding to 29 paired patients, but the mutation frequencies were calculated considering the 33 paired cases with 66 samples.

There were some differences in the frequency of additional mutations depending on the local or distant nature of the CM. In the 17 paired cases that developed distant CM, additional alterations in the CM with respect to the primary tumors were found in 11 cases (64.7%) (5 TN, 4 Luminal HER2-, and 2 HER2+). In contrast, among the 15 paired cases that developed local CM, only 5 cases (33.3%) (3 TN, 1 Luminal HER-, and 1 HER2+) showed additional molecular alterations. (Table 4).

In addition, 11 mutations were confirmed in the TP53, PIK3CA, and ERBB2 genes. Figure 3 shows the different mutations found in the ERBB2 gene (L755S and S310F) between the primary tumor and the MC of Pt13, as well as the verification by Sanger.
Table 3. Pathogenic alterations in primary tumors and their cutaneous metastasis.

| Surrogate Molecular Types | Gene | Primary Tumors n (%) | Cutaneous Metastases n (%) |
|---------------------------|------|----------------------|---------------------------|
| **TN** n = 12 Mutations  | TP53 | 10 (83)              | 11 (92)                   |
|                           | PIK3CA | 2 (17)               | 4 (33)                    |
|                           | NF1 | 1 (8.3)               | 1 (8.3)                   |
| **TN** n = 7 CNVs        | MYC | 1 (14.3)              | 3 (42.9)                  |
|                           | MDM4 | 0                     | 1 (14.3)                  |
|                           | FGFR1 | 1 (14.3) | 1 (14.3) |
| **Luminal HER2-** n = 16 Mutations | TP53 | 1 (6)               | 1 (6)                     |
|                           | PIK3CA | 7 (39)               | 7 (39)                    |
|                           | NF1 | 1 (6.2)               | 2 (12.5)                  |
|                           | AKT1 | 2 (12.5)              | 2 (12.5)                  |
| **Luminal HER2-** n = 9 CNVs | MYC | 1 (11.1)              | 1 (11.1)                  |
|                           | MDM4 | 0                     | 1 (11.1)                  |
|                           | CCND1 | 1 (11.1)          | 0                         |
| **HER2+** n = 5 Mutations | TP53 | 2 (40)               | 2 (40)                    |
|                           | PIK3CA | 4 (80)               | 4 (80)                    |
|                           | NF1 | 1 (20)                | 1 (20)                    |
|                           | AKT1 | 1 (20)                | 1 (20)                    |
| **HER2+** n = 4 CNVs     | MYC | 1 (25)                | 1 (25)                    |
|                           | MDM4 | 0                     | 1 (25)                    |
|                           | FGFR1 | 1 (25)            | 1 (25)                    |
|                           | CCND1 | 0                     | 1 (25)                    |

3.5. Survival Analysis

In our series, 7 patients were alive and 26 had died when the data were censored. The median survival since the diagnosis of the disease was 53 months and the median survival since the diagnosis of the CM was 19.6 months. Of the patients who developed distant CM, the median survival was 14.5 months, with an overall survival in the first year of 46.7% of patients. In contrast, when MC was local, the median survival was 34.6 months, with an overall survival in the first year of 40% of patients.

The association between overall survival since the diagnosis of the primary tumor and age, location (local or distant), pT, pN, clinical stage, surrogate molecular type and histological type, histological grade, LIV, and neoadjuvant therapy were assessed. In addition, the association between overall survival and TP53 and PIK3CA mutations was assessed. Histological grade, surrogate molecular type, and TP53 mutations significantly affect overall survival ($p = 0.015$, $p = 0.0011$ and $p = 0.019$, respectively) (Figure 4a–c). The shortest overall survival was observed in the TN surrogate molecular type (Figure 4a). By multivariate analysis with the 3 significant variables, the only independent variable in the CoxPh analysis was surrogate molecular type, where HER2- Luminal was the best prognostic type. (Figure 4d).

In contrast, the variables pT, pN, stage, permeation, age, histological type location (local or distant), neoadjuvant therapy, or PIK3CA mutations did not significantly affect overall survival.
Figure 2. (a) Hematoxylin-eosin of a primary breast tumor and its corresponding cutaneous metastasis. (b) Fluorescent In-Situ Hybridization of the FGFR1 gene in the primary breast tumor (without CNV) and in the cutaneous metastasis (with polysomy). 100×.

Table 4. Additional molecular alteration in cutaneous metastases not found in primary tumors of paired cases.

| Location                        | Surrogated Molecular Type       | Gene                              | Cases with Additional Mutation in Cutaneous Metastasis |
|---------------------------------|---------------------------------|-----------------------------------|--------------------------------------------------------|
| Distant cutaneous metastasis    | TN                              | PIK3CA, RB1, FGFR2 + MYC (amplification), CTNNB1, MDM4 (amplification) | 1                                                      |
| n = 17                          | Luminal HER2-                   | FGER1 + NF1, BRCA2 + MKI67 + SF3B1, CASP8 + ERBB2, MDM4 (amplification) | 1                                                      |
|                                 | HER2+                           | KRAS + CCND1 (amplification) + MDM4 (amplification), BRCA1 + FGFR1 (polysomy) | 1                                                      |
| Local cutaneous metastasis      | TN                              | TP53 + PIK3CA + COLIA1, PIK3CA, MYC (amplification) | 1                                                      |
| n = 15                          | Luminal HER2-                   | ERBB2 (polysomy)                 | 1                                                      |
|                                 | HER2+                           | MYC (amplification)              | 1                                                      |

When not specified as an amplification, the alteration detected was a mutation.
Figure 3. (a) Visualization in the IGV software of different ERBB2 mutations found in the primary tumor and the cutaneous metastasis in patient Pt13. (b) Orthogonal validation by the Sanger sequencing.

Surrogated molecular Type

Figure 4. Cont.
Figure 4. Kaplan–Meyers graphs showing the association between overall survival and the surrogate molecular type (a), histological grade (b), and TP53 status (c). (d) Multivariate analysis showing the independent prognostic significance of the surrogate molecular type.

4. Discussion

4.1. Clinicopathologic Features of Breast Carcinomas That Develop Cutaneous Relapses

In this study, the clinicopathological features were analyzed of 33 females with BC that developed cutaneous metastases, distantly in 53.1% and locally in 46.9% of the patients. Our observation that 46.9% of CM developed locally on the skin of the breast/thorax is in accordance with the review by Johnson et al. [24], who found in a study of 61 patients with CM, 57% showed metastases in the breast/thorax skin.

In the present series, CM developed at a median of 22.8 months after the initial diagnosis of the primary BC. CM usually appear at the end of the disease, late during cancer evolution. Thus, Lookingbill et al. [25] found that only 6.3% of patients with BC had cutaneous involvement at the time of diagnosis of the primary tumor. More recently, Johnson et al. [24] reported that approximately 13.7% of the patients in the 9 retrospective series reviewed [26–34] had a skin lesion before or simultaneously with the diagnosis of BC. Supporting these observations, we found that 18.2% of patient in the present series debuted with skin involvement.

The median age of women with BC who developed CM varies among series. Whereas the age in our series (63.5 years) was similar to the Johnson et al. [24] review of 41 patients, other studies have reported a mean of 74 years (n = 18) [9] and 48 years (n = 125) [15]. These differences may be related with the different number of patients included in each series or due to ethnic/geographic differences, since these series originated from Italy, South Korea, and Spain.

In the present series, the histology of 24 cases (72.7%) corresponded to BCNST, and the rest to special histologic subtypes. Among them, the largest group corresponded to ILC (21.2%). However, considering only the 16 Luminal HER2- cases in our series, 43.7% were ILC. Since the frequency of ILC in Luminal HER2- BC is between 15% and 20% [35], our results suggested that ILC is a major risk factor for developing skin metastases. In accordance with our results, the study of Li et al. [36] that included only metastases from Luminal HER2- BC, reported that the proportion of ILC was 26% in the group of patients that developed CM.

We observed that the frequency of BC developing CM varied according to the subtype. Table 5 compares the data from our series with those from other published series [15,37–39],
including our recently published CM review that includes samples \( n = 58 \) of molecularly characterized CM \([39–43]\).

**Table 5.** Distribution of surrogated molecular types in breast cancer with cutaneous metastasis in different series.

| Authors                        | n  | Luminal HER2– \( n \) (%) | HER2+ \( n \) (%) | TN \( n \) (%) | Unknown \( n \) (%) |
|-------------------------------|----|-----------------------------|-------------------|----------------|-------------------|
| Yates y col. \([39]\)          | 19 | 9 (47)                      | 2 (10)            | 5 (26)         | 3 (16)            |
| Kong y col. \([15]\)           | 125| 53 (42.4)                   | 43 (34)           | 29 (23)        |                   |
| Luna y col. \([38]\)           | 26 | 7 (27)                      | 7 (27)            | 10 (39)        | 2 (7)             |
| González-Martínez y col. \([37]\) | 58 | 29 (50)                     | 8 (14)            | 15 (26)        | 6 (10)            |
| Present series                 | 33 | 16 (48.5)                   | 5 (15.2)          | 12 (36.4)      |                   |

Although there were differences between series, a finding common to all of them is the relative overrepresentation of TNBC, since its frequency in the general population of BC is around 15% \([44]\), but it was between 23–39% in BC with CM, suggesting that this surrogate molecular type could be associated with a greater potential to metastasize to the skin.

In our series, 15.2% of BC that developed CM were HER2+, a frequency similar to the general population of BC, at least in Spain, suggesting that this surrogate molecular type does not have a special propensity to develop CM. However, Table 5 shows important differences in the frequency of HER2+ BC that develop CM among different series. These differences are probably due to differences in sample size, patient selection, methods of HER2 detection and the period of study.

**4.2. Molecular Alterations Involved in the Development of Cutaneous Metastasis in Breast Cancer**

In this series, we studied the mutational landscape of 33 matched primary tumors with their corresponding CM by NGS. In addition, changes in copy number of \( CCND1, FGFR1, MDM4 \) and \( MYC \) were analyzed by FISH in 20 paired samples. The molecular landscape of primary tumors in this series was concordant with many previous reports demonstrating different mutational patterns among different surrogate molecular types. Thus, whereas mutations in \( PIK3CA \) predominated among Luminal BC, \( TP53 \) mutation was the main molecular alteration in TNBC.

When primary tumors were compared with their respective metastasis, we found that 48.5% of CM exhibited additional pathogenic mutations and/or gene amplification in important oncogenes and/or tumor suppressor genes. Genes involved in the progression of more than one case in the present series included \( MYC, MDM4, PIK3CA \) and \( ERBB2 \). In spite of this high frequency of additional changes, we did not observe a specific mutational pattern related to tumor progression, indicating that CM is a very individual process in each tumor. These results add to the observations of three previous series analyzing paired primary BCs and their CMs including a total of only 15 patients \([39]\) (Table 6).

There are several studies analyzing molecular alterations in metastatic BC including samples from CM, but without comparison with their primary tumors (see González-Martínez et al. \([37]\)). In general, these studies also confirmed that there is no specific pattern of mutations that predispose to CM. Only Rinaldi et al. \([39]\) observed that alterations in \( NOTCH1 \) were overrepresented in CM when compared to other metastatic locations.

We observed that the number of CM with additional molecular alterations was higher in distant than local metastases. Thus, additional mutations and CNVs were observed in 11 out of 17 (64.7%) distant CM but in only 5 out 15 (33.3%) local CM. These differences seemed to indicate a more advanced molecular stage of distant CM, although they did not have prognostic implications.
Table 6. Additional mutations in cutaneous metastases reported in different series.

| Authors                  | Paired Cases of Cutaneous Metastases | Cases with Additional Mutation | Additional Molecular Alterations in Cutaneous Metastases                        |
|--------------------------|-------------------------------------|-------------------------------|---------------------------------------------------------------------------------|
| Schrijver and col. [41]  | 8 *                                 | 6                             | 33 mutations (ATR, BRCA1, SMAD4, CDH1, ARID1A, ERBB2, IDH1, PIK3R1, RB1, etc.) and FGF3 amplification |
| Cohort 1: 2              |                                     |                               | 4 molecular alterations (FGFR1 amplification/TP53 structural variant, RB1 indel/TERC amplification) |
| Cohort 2: 4              |                                     |                               | 8 mutations (JAK2, NF1, TP53, AKTI, ARID1A, ARID1A, RB1) and 2 amplifications (MYC and FGFR1) |
| Yates and col. [39]      |                                     |                               |                                                                                |
| Paul and col. [42]       | 1                                   | 1                             | 54 mutations (PIK3CA, TP53, etc.)                                               |
| Present series           | 33                                  | 17                            | 12 TN 6 mutations (TP53 + PIK3CA + COL1A1, PIK3CA, RB1, FGFR2, CTNNB1) and 3 amplifications (2 in MYC and one in MDM4) |
|                          |                                     |                               | 7 mutations (FGFR1 + NFI, BRCA2 + M5667 + SF3BI, CASP8+ ERBB2) and 2 amplifications or polysomy (ERBB2 and MDM4) |
|                          |                                     |                               | 2 mutations (KRAS, BRCA1), 4 amplifications or polysomy (CCND1, MYC, FGFR1 and MDM4) |

* Of these 8 cases, 2 had no additional molecular alterations in cutaneous metastasis.

It is also worth noting that there was hardly any difference between the mutation frequency of TP53 and PIK3CA in CM samples of patients diagnosed at early and advanced stages, so we assume that treatment has no effect on the mutation pattern.

4.3. Therapeutic Implications

An important question in the study of cancer metastasis is whether or not the molecular characteristics of metastatic samples modify patient treatment. In 5 patients in this study (15.1%), there was a conversion of the surrogate molecular type between the primary tumor and its CM. In 3 cases (9%), there was a change from luminal to TN, from Luminal HER2+ to Luminal HER2- in one case (3%), and from Luminal HER2- to Luminal HER2+ in another case (3%). All these changes would have impacted on the treatment decision regarding the use of hormone therapy or anti-HER2 therapy.

Regarding specific mutations, three CM developed additional PIK3CA mutations, which is a target for treatment with alpelisib in RH+ metastatic BC. However, the three primary and metastases were TN. We detected an ESR1 mutation in a primary HR+ tumor and the corresponding CM. ESR1 mutations are the most frequent additional mutations that develop in metastatic HR+ BC after hormone therapy, especially after the use of aromatase inhibitors, being infrequent in primary tumors. In this case, ESR1 mutations would have influenced the response to hormone therapy during the complete evolution of the disease.
An interesting case in this series was the tumor and the CM developed in patient Pt13, which was an ILC that carried the pathogenic L755S mutation in the primary tumor. This mutation was absent in the CM, which carried the pathogenic mutation S310F. ERBB2 mutations are more frequent in ILC (6%) than in IDC (1.5%), especially in ILC with pleomorphic features, and are associated with a poor prognosis in ILC [45,46]. In addition, response to different anti-HER2 therapies differed among mutations. Thus, whereas L755S seems to be resistant to trastuzumab and lapatinib but sensitive to neratinib and afatinib, S310F seems to be sensitive to all drugs.

4.4. Prognosis

Patients with CM have a very poor prognosis. Lookingbill et al. [47] observed an average survival of 31 months after the diagnosis of the CM. Kong et al. [15] observed a median survival of 32 months. In our series, the median survival was 19.6 months, and this difference may be related to the clinical differences between the series. Additionally, patients who developed distant CM had a shorter overall survival and died more frequently during the first year after the diagnosis of CM. However, these differences between survival according to location were not statistically significant. In the univariate survival analysis, the only three variables that showed an impact on prognosis were the histological grade, the surrogate molecular type, and TP53 mutations. However, in the multivariate analysis, only the surrogate molecular type remained statistically significant, and the Luminal HER2-surrogate molecular type had a better prognosis.

4.5. Study Limitations

One limitation of this study is the relatively low number of cases studied. However, in spite of this and to the best of our knowledge, this is the largest series analyzing matched primary tumors and CMs reported so far. In addition, a comprehensive NGS panel of 61 genes was used in this study, including the most frequently mutated genes in BC. However, there may be additional genes with a role in progression in individual tumors that were not included in the panel. Moreover, the panel was not designed to detect CNVs or gene rearrangements, although this limitation was resolved in part by analyzing the genes most frequently amplified in BC by FISH.

Further research in this field would require studies with a larger number of patients and samples and perhaps focused on patients with BC of the TN surrogated molecular type, as this seems to be not only the most likely to metastasize to the skin but also has the poorest prognosis.

5. Conclusions

The development of new strategies for the management of CMs is a major clinical challenge because of the poor prognosis. To advance in this field, a better understanding of the molecular alterations involved in the metastatic process is needed. In the present study, the clinicopathological characteristics of BCs developing CM was analyzed and compared to the molecular differences between primary breast tumors and their corresponding CMs. We observed that the surrogate molecular type of BC with a greater risk to metastasize to skin was TN. A change of tumor surrogate molecular type in metastases with an impact on treatment was found in 15% of patients. In addition, half of the CM presented some additional molecular alterations with respect to the primary tumors, but a characteristic molecular pattern related to tumor progression and CM development was not observed. In this series, survival was related to the tumor surrogate molecular type. The immunohistochemical and molecular analysis of BC CM is essential for a proper treatment of the patients.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14051151/s1, Table S1: Mutations and primers used for Sanger verifications. Table S2: Clinicopathological features of the 33 patients; Table S3: List of somatic mutations found in the breast cancer and cutaneous metastases subjected to NGS analysis.

Author Contributions: Conceptualization, S.G.-M., J.C. and J.P.; methodology, S.G.-M., D.P., T.C.-C. and B.P-M.; validation, S.G.-M., B.P.M. and J.P.; formal analysis, S.G.-M. and D.P.; investigation, S.G.-M., resources, J.C., J.L.R.-P. and J.P.; data curation, S.G.-M.; writing—original draft preparation, S.G.-M.; writing—review and editing, J.C., J.P., S.G.-M., D.P., B.P.M., T.C.-C., J.L.R.-P., G.C., M.G. and A.C.; visualization, S.G.-M., J.C. and J.P.; supervision, J.C. and J.P.; funding acquisition, J.C. and J.P.; project administration, J.C. and J.P. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by grants from the Instituto de Salud Carlos III (ISCIII) (PI19/01331) and CIBERONC (CB16/12/00316 and CB16/12/00449), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (FEDER), and by the Spanish Association Against Cancer Scientific Foundation (Grupos Coordinados Traslacionales aec 2018).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hospital Ramón y Cajal (Madrid, Spain) (protocol code 30-21 19/05/2021).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: “Contigo contra el Cáncer de la Mujer” Foundation.

Conflicts of Interest: J.C.: consulting/Advisor: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Kyowa Kirin. Honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo. Research funding to the institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanath health, Merck Sharp&Dohme, Pfizer, Piqrur Therapeutics, Puma C, Queen Mary University of London. Stock, patents, and intellectual property: MedSIR. Travel, accommodation, expenses: Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Torre, L.A.; Islami, F.; Siegel, R.L.; Ward, E.M.; Jemal, A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol. Biomark. Prev. 2017, 26, 444–457. [CrossRef]
2. Tsang, J.Y.S.; Tse, G.M. Molecular Classification of Breast Cancer. Adv. Anat. Pathol. 2020, 27, 27–35. [CrossRef] [PubMed]
3. Yam, C.; Mani, S.A.; Moulder, S.L. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist 2017, 22, 1086–1093. [CrossRef] [PubMed]
4. World Health Organization Classification of Tumours Editorial Board; International Agency for Research on Cancer; World Health Organization. WHO Classification of Tumours. Breast Tumours; International Agency for Research on Cancer: Lyon, France, 2017; ISBN 978-92-832-4500-1.
5. Scully, O.J.; Bay, B.-H.; Yip, G.; Yu, Y. Breast cancer metastasis. Cancer Genom. Proteom. 2012, 9, 311–320.
6. Chiang, A.C.; Massagué, J. Molecular Basis of Metastasis. N. Engl. J. Med. 2008, 359, 2814–2823. [CrossRef]
7. Liotta, L.A. Cancer invasion and metastases. Adv. Anat. Pathol. 1990, 263, 1123–1126. [CrossRef]
8. Arozullah, A.M.; Calhoun, E.A.; Wolf, M.; Finley, D.K.; Fitzner, K.A.; Becking, E.A.; Gorby, N.S.; Schumock, G.T.; Bennett, C.L. The financial burden of cancer: Estimates from a study of insured women with breast cancer. J. Support. Oncol. 2004, 2, 271–278. [PubMed]
9. Guanziroli, E.; Coggi, A.; Venegoni, L.; Fanci, D.; Ercoli, G.; Boggio, F.; Veraldi, S.; Berti, E.; Gianotti, R.; Ferrero, S.; et al. Cutaneous metastases of internal malignancies: An experience from a single institution. Eur. J. Dermatol. 2017, 27, 609–614. [CrossRef]
10. de Bittencourt, M.J.S.; Carvalho, A.H.; do Nascimento, B.A.M.; Freitas, L.K.M.; de Parijos, A.M. Cutaneous metastasis of a breast cancer diagnosed 13 years before. An. Bras. Dermatol. 2015, 90, 134–137. [CrossRef]
11. De Giorgi, V.; Grazzini, M.; Alaioli, B.; Savarese, I.; Corciova, S.A.; Guerriero, G.; Lotti, T. Cutaneous manifestations of breast carcinoma: A clinical guide. Dermatol. Ther. 2010, 23, 581–589. [CrossRef] [PubMed]
12. Alcaraz, I.; Cerroni, L.; Rütten, A.; Kutzner, H.; Requena, L. Cutaneous Metastases From Internal Malignancies: A Clinicopathologic and Immunohistochemical Review. *Am. J. Dermatopathol.* 2012, 34, 347–393. [CrossRef] [PubMed]

13. Tan, A.R. Cutaneous manifestations of breast cancer. *Semin. Oncol.* 2016, 43, 331–334. [CrossRef] [PubMed]

14. Hu, S.C.-S.; Chen, G.-S.; Wu, C.-S.; Chai, C.-Y.; Chen, W.-T.; Lan, C.-C.E. Rates of cutaneous metastases from different internal malignancies: Experience from a Taiwanese medical center. *J. Am. Acad. Dermatol.* 2009, 60, 379–387. [CrossRef]

15. Kong, J.H.; Park, Y.H.; Kim, J.A.; Kim, J.H.; Yun, J.; Sun, J.M.; Won, Y.W.; Lee, S.; Kim, S.T.; Cho, E.Y.; et al. Patterns of Skin and Soft Tissue Metastases from Breast Cancer according to Subtypes: Relationship between EGFR Overexpression and Skin Manifestations. *Oncology* 2011, 81, 55–62. [CrossRef]

16. Krathen, R.A.; Orengo, I.F.; Rosen, T. Cutaneous Metastasis: A Meta-Analysis of Data. *South Med. J.* 2003, 96, 164–167. [CrossRef]

17. Brownstein, M.H.; Helwig, E.B. Metastatic tumors of the skin. *Cancer* 1972, 29, 1298–1307. [CrossRef]

18. Moore, S. Cutaneous Metastatic Breast Cancer. *Clin. J. Oncol. Nurs.* 2002, 6, 255–260. [CrossRef]

19. Marcoval, J.; Gallego, M.I.; Moreno, A. Inflammatory Cutaneous Metastasis as a First Sign of Recurrence of Squamous Cell Carcinoma of the Lung. *Actas Dermo-Sifiliogr.* Ed. 2008, 99, 157–159. [CrossRef]

20. Lin, L.; Sirohi, D.; Coleman, J.F.; Gulbahce, H.E. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. *Am. J. Clin. Pathol.* 2019, 152, 479–485. [CrossRef] [PubMed]

21. Koboldt, D.C.; Zhang, Q.; Larson, D.E.; Shen, D.; McLellan, M.D.; Lin, L.; Miller, C.A.; Mardis, E.R.; Ding, L.; Wilson, R.K. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 2012, 22, 568–576. [CrossRef] [PubMed]

22. Robinson, J.T.; Thorvaldsdóttir, H.; Winckler, W.; Guttmann, M.; Lander, E.S.; Getz, G.; Mesirov, J.P. Integrative genomics viewer. *Nat. Biotechnol.* 2011, 29, 24–26. [CrossRef] [PubMed]

23. Turner, N.C.; Reis-Filho, J.S. Tackling the Diversity of Triple-Negative Breast Cancer. *Clin. Cancer Res.* 2013, 19, 6380–6388. [CrossRef]

24. Johnson, C. Cutaneous Manifestation as Initial Presentation of Metastatic Breast Cancer: A Systematic Review. *Cutis* 2021, 107, E29–E36. [CrossRef] [PubMed]

25. Lookingbill, D.P.; Spangler, N.; Sexton, F.M. Skin involvement as the presenting sign of internal carcinoma. *Am. J. Dermatopathol.* 1990, 12, 19–26. [CrossRef] [PubMed]

26. Atı̇s, G.; Tükenmez Demirci, G.; Kıvanç Atunay,˙I.; Sakız, D. Derinin metastatik tümörlerinin primer deri tümörleri arasındaki sıklığı ve klinik özellikleri. *Turkderm* 2013, 47, 166–169. [CrossRef]

27. Bansal, R.; Patel, T.; Sarin, J.; Parikh, B.; Ohi, A.; Trivedi, P. Cutaneous and subcutaneous metastases from internal malignancies: An analysis of cases diagnosed by fine needle aspiration. *Diagn. Cytopathol.* 2011, 39, 882–887. [CrossRef]

28. Bennoursy, R.; Souissi, A.; Badri, T.; Ben Jannet, S.; Marrak, H.; Mokhtar, I.; Fenniche, S. Cutaneous metastases from internal cancers. *Acta Dermatovenerol. Alp. Pannonica Adriat.* 2008, 17, 167–170. [PubMed]

29. Chopra, R.; Chhabra, S.; Samra, S.G.; Thami, G.P.; Punia, R.P.S.; Mohan, H. Cutaneous metastases of internal malignancies: A clinicopathologic study. *Indian J. Dermatol.* *Venerol. Leprol.* 2010, 76, 125–131. [CrossRef]

30. El Khoury, J.; Khalifeh, I.; Kibbi, A.-G.; Abbas, O. Cutaneous metastasis: Clinicopathological study of 72 patients from a tertiary care center in Lebanon. *Int. J. Dermatol.* 2014, 53, 147–158. [CrossRef] [PubMed]

31. Fernandez-Flores, A. Cutaneous metastases: A study of 78 biopsies from 69 patients. *Am. J. Dermatopathol.* 2010, 32, 222–239. [CrossRef]

32. Gómez Sánchez, M.E.; Martínez Martínez, M.L.; Martín De Hijas, M.C.; López Villaescusa, M.T.; Faura Berruga, C.; Rodríguez Vázquez, M.; Pérez García, L.J. Metastasis cutáneas de tumores sólidos. Estudio descriptivo retrospectivo. *Piel* 2014, 29, 207–212. [CrossRef]

33. Handa, U.; Kundu, R.; Dimri, K. Cutaneous Metastasis: A Study of 138 Cases Diagnosed by Fine-Needle Aspiration Cytology. *Acta Cytol.* 2017, 61, 47–54. [CrossRef] [PubMed]

34. Itin, P.; Tomashcett, S. Hautmetastasen bei viszeralen Malignomen: Eine epidemiologische Studie. *Internist* 2009, 50, 179–186. [CrossRef] [PubMed]

35. Razavi, P.; Chang, M.T.; Xu, G.; Bandlamudi, C.; Ross, D.S.; Vasan, N.; Cai, Y.; Bielski, C.M.; Donoghue, M.T.A.; Jonsson, P.; et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. *Cancer Cell* 2018, 34, 427–438.e6. [CrossRef]

36. Li, Q.; Jiang, B.; Guo, J.; Shao, H.; Del Priore, I.S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. *Cancer Discov.* 2021, 12, 356–371. [CrossRef] [PubMed]

37. Gonzalez-Martinez, S.; Pizarro, D.; Perez-Mies, B.; Caniego-Casas, T.; Curigliano, G.; Cortés, J.; Palacios, J. Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. *Cancers* 2021, 13, 5416. [CrossRef]

38. Luna, A.; Rabassa, M.E.; Isla Larrain, M.; Cabaleiro, P.; Zwenger, A.; Canzoneri, R.; Segal-Eiras, A.; Abba, M.C.; Croce, M.V. Breast cancer cutaneous metastases are associated to uMUC1 and sialyl Lewis x and to highly malignant primary tumors. *Pathol.-Res. Pract.* 2020, 216, 152859. [CrossRef]

39. Yates, L.R.; Knappskog, S.; Wedge, D.; Farmery, J.H.R.; Gonzalez, S.; Martincorena, I.; Alexandrov, L.B.; Van Loo, P.; Haugland, H.K.; Lilleg, P.K.; et al. Genomic Evolution of Breast Cancer Metastasis and Relapse. *Cancer Cell* 2017, 32, 169–184.e7. [CrossRef]

40. Lefebvre, C.; Bachelor, T.; Filleron, T.; Pedrero, M.; Campone, M.; Soria, J.-C.; Massard, C.; Lévy, C.; Arnedos, M.; Lacroix-Triki, M.; et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. *PLoS Med.* 2016, 13, e1002201. [CrossRef]
41. Schrijver, W.A.; Selenica, P.; Lee, J.Y.; Ng, C.K.Y.; Burke, K.; Piscuoglio, S.; Berman, S.H.; Reis-Filho, J.S.; Weigelt, B.; Van Diest, P.J.; et al. Mutation profiling of key cancer genes in primary breast cancers and their distant metastases. Cancer Res. 2018, 78, 3112–3121. [CrossRef]

42. Paul, M.R.; Pant, D.K.; Shih, N.N.C.; Chen, Y.; Harvey, K.L.; Solomon, A.; Lieberman, D.; Morrissette, J.J.D.; Soucier-Ernst, D.; Goodman, N.G.; et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J. Clin. Investig. 2020, 130, 4252–4265. [CrossRef]

43. Muller, K.E.; Marotti, J.D.; de Abreu, F.B.; Peterson, J.D.; Miller, T.W.; Chamberlin, M.D.; Tsongalis, G.J.; Tafe, L.J. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers. Exp. Mol. Pathol. 2016, 100, 421–425. [CrossRef] [PubMed]

44. Morris, G.J.; Naidu, S.; Topham, A.K.; Guiles, F.; Xu, Y.; McCue, P.; Schwartz, G.F.; Park, P.K.; Rosenberg, A.L.; Brill, K.; et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 2007, 110, 876–884. [CrossRef]

45. Kurozumi, S.; Alsaleem, M.; Monteiro, C.J.; Bhardwaj, K.; Joosten, S.E.P.; Fujii, T.; Shirabe, K.; Green, A.R.; Ellis, I.O.; Rakha, E.A.; et al. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: A retrospective in silico analysis of public datasets. Breast Cancer Res. 2020, 22, 85. [CrossRef] [PubMed]

46. Rosa-Rosa, J.; Caniego-Casas, T.; Leskela, S.; Cristobal, E.; González-Martínez, S.; Moreno-Moreno, E.; López-Miranda, E.; Holgado, E.; Pérez-Mies, B.; Garrido, P.; et al. High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers 2019, 11, 74. [CrossRef]

47. Lookingbill, D.P.; Spangler, N.; Helm, K.F. Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients. J. Am. Acad. Dermatol. 1993, 29, 228–236. [CrossRef]